ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

NCI funds nine centers for $14.9 million integrative biology program.

October 29, 2004

NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.

April 20, 2007

ORI Final Findings Of Scientific Misconduct

September 16, 1994

FDA To Regulate Products From Human Cells, Tissue

March 21, 1997

Children With Recurrent Hodgkin’s Respond To Gemcitabine, Vinorelbine

March 27, 2009

In Brief: Glick, Armitage Lead ASCO; NCAB Approves Resolution Calling For Higher NIH Budget

June 2, 1995